This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?

Metformin — life begins at 50

A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007

Consultant Physician, Victoria Hospital, Hayfield Road, Kirkcaldy, Fife, KY2 5AH, UK, jackie.wallace{at}faht.scot. nhs.uk

References

• Bailey CJ, Day C. Metformin: its botanical background. Practical Diabetes Int 2004;21:115-17.[CrossRef]
• Hadden DR Goat's rue - French lilac - Italian fitch - Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection. J R Coll Physicians Edin 2005;35:258-60.
• Joslin EP Proceedings of the nineteenth annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, USA, May 2, 1927. J Clin Invest 1927;4:435-6.
• Sterne J. Du Nouveau dans les antidiabétiques. La NN diméthylamino guanyl guanidine (N.N.D.G.). Maroc Med 1957;36:1295-6.
• Rambert P., Canivet J., Quichaud F., Spitz B. Treatment of diabetes mellitus with NNdimethil-diguanide. La Medecin en France. 1961;September:29-37.
• Shaw RJ, Lamia KA, Vasquez D. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310:1642-6.[Abstract/Free Full Text]
• UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit-Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kao J., Tobis J., McClelland RL et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347-50.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Scarpello JH Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29:6S36-6S43.[Medline] [Order article via Infotrieve]
• Sgambato S., Varricchio M., Tesauro P., Passariello N., Carbone L. L'utilisation de la metformin dans la cardiopathie ischemique. Clin Ter 1980;94:77-85.[Medline] [Order article via Infotrieve]
• Mather KJ, Verma S., Anderson TJ Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37:1344-50.[Abstract/Free Full Text]
• Katakami N., Yamasaki Y., Hayaishi-Okano R. et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes. Diabetologia 2004;47:1906-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Garber AJ, Duncan TG, Goodman AM et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fujioka K., Brazg RL, Raz I. et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab 2005;7:28-39.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Saenz A., Fernandez-Esteban I., Mataix A. et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; CD002966.
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.. N Engl J Med 2006;355:2427-43.[Abstract/Free Full Text]
• Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.[Abstract/Free Full Text]
• DeFronzo RA, Ratner RE, Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.[Abstract/Free Full Text]
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.[Abstract/Free Full Text]
• Ramachandran A., Snehalatha C., Mary S. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49:289-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wenying Y., Lixiang L., Jinwu Q., et al. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3 year multicentral prospective study. Chin J Endocrinol
• Metab 2001;17:131-4. 23. Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-9.[Free Full Text]
• Alberti KG, Zimmet P., Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med 2007;24:451-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• National Institute for Health and Clinical Excellence. Guideline CG11 Fertility. Available at http://www.nice.org.uk/guidance/CG11/guidance/pdf/English (accessed March 2007).
• American Association of Clinical Endocrinologists. Position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Available at http://www.aace.com/pub/pdf/guidelines/PCOSpositionstatement.pdf (accessed October 2007)
• Evans JM, Donnelly LA, Emslie-Smith AM et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304-05.[Free Full Text]
• Bowker SL, Majumdar SR, Veugelers P., Johnson JA Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8.[Abstract/Free Full Text]
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21 and Diabetes Care 2006; 29:1963-72.[Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 5, 247-252 (2007)
DOI: 10.1177/14746514070070051001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?